RedMedEd
@RedMedEd
Followers
282
Following
296
Media
768
Statuses
2K
Redefining Medical Education
Malvern, PA
Joined December 2013
Ready, set… hunt! 👀 Join the first-ever #ASHScavengerHunt at #ASH25! Explore, snap, and share your experience at the 2025 ASH Annual Meeting and Exposition. Register now: https://t.co/9hOe8b23Jz
1
13
25
Looking for CME with challenging bladder cancer cases? Try our online, interactive Clinical Callout on emerging options for bladder cancer care: https://t.co/J2XFEtr2C7 with @ERPlimackMD and @BladderCancerUS
0
0
0
Our online mobile-friendly CME activity on advances in RRMM management https://t.co/ogO7l3sL3p, includes downloadable tools that are sure to be invaluable to your practice. @theMMRF; @HJChoMDPhD1 #mmsm
0
0
0
Bladder cancer care professional development for APPs—game show style with @BladderCancerUS and Colleen Tetzlaff @Onc_PA_Mom! Don’t just sit in the studio audience: play a round today! https://t.co/yq7Wswvu99
0
0
0
Good news for myeloma patients #mmsm
https://t.co/iZmhH5UIlM
gsk.com
Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care.
1
3
9
Such a huge loss for the myeloma community. Condolences to Dr. Durie's family and friends.
It is with great sadness that the International Myeloma Foundation (IMF) shares the news of the death of Dr. Brian G.M. Durie, co-founder of the organization. Read the press release: https://t.co/zf7u4psgNR
@jmikhaelmd
@VincentRK
1
2
3
Is your knowledge of bladder cancer care up to date?Our CME-accredited Q-Challenge activity tests your knowledge of—and provides insights on—the latest advances: https://t.co/3lVGHfuBhf
@BladderCancerUS
0
0
1
Designed with a slick, streamlined interface optimized for mobile devices, our newest interactive CME activity on recent advances in RRMM management is now available! @theMMRF #mmsm Start here ➡️ https://t.co/0oNimXXR24
0
0
1
From No Hope to a Potential Cure for a Deadly Blood Cancer @ginakolata #mmsm #ciltacel
https://t.co/Y8xTSKk04d
nytimes.com
Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.
1
5
17
The @US_FDA ODAC recommends approval of daratumumab (Darzalex) for high-risk smoldering myeloma. The MMRF supports access to safe and effective treatments for all patients and research to better define this population. #MultipleMyeloma #theMMRF
0
5
16
An @US_FDA ODAC will be held May 20th to discuss the potential approval for Dara in smoldering myeloma #mmsm Very good points made in the discussion 👇 ➡️ https://t.co/5WlEaR7shQ Few important observations summarised here🧵
2
10
34
1/3🧵 🔥Hot off the press. ⭐️My co-authors & I are excited to share this just published paper @ASCO #ASCO25 #ASCOEdBook on a topic that is near & dear to my heart: ✅“The ART of #Oncology #Education & #Knowledge Sharing. It is All About the “#How” 👇🏻 https://t.co/R6v2snvwp7
4
43
138
🔬 1,100+ #myeloma patients. 10+ years of data. The largest clinical-genomic study of its kind: the MMRF CoMMpass℠ Study. It's supported 100+ peer-reviewed papers, and countless abstracts & presentations worldwide. Learn more: https://t.co/RONH3CQlqW
#NationalCancerResearchMonth
0
1
4
Explore how novel therapies are changing bladder cancer care with @ERPlimackMD, Shilpa Gupta, MD, & BladderCancerUS
reachmd.com
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic...
0
0
0
Explore the latest advancements in bispecific antibody therapy for relapsed/refractory multiple myeloma in @theMMRF's episode of Myeloma Matters for clinicians. #mmsm
reachmd.com
Release date: 8/15/2024Expiration date: 8/15/2025Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This episode of Myeloma Matters reviews the latest data on...
0
1
1
In this activity @BerdejaJesus and @AjaiChari review the unique benefits and risks of bispecific antibodies for myeloma. #mmsm @themmrf Don’t delay: this activity expires on Thursday, May 1.
mycme.com
This not-for-credit activity reviews strategies for safely incorporating myeloma bispecific antibody therapy into practice, with a focus on managing treatment-related AEs. Exp 5/1/25
0
0
1
Check out @themmrf enhanced podcast for expert and patient insights on bispecific antibodies in multiple myeloma. #mmsm with @BerdejaJesus @AjaiChari
0
0
0
Our roundtable has convened with @DoctorAKrishnan, @szusmani and @ZainabShd as they discuss innovative CD38 antibody quadruplet regimens, which offer the promise of improved depth of response for patients newly diagnosed with multiple myeloma #mmsm
mycme.com
1.00 CME: Features expert discussion and evidence-based presentations on the use of CD38-targeted therapy to optimize outcomes for newly diagnosed myeloma. Exp 8/30/25
0
5
5